Conclusion: The outlook for state Medicaid coverage of GLP-1 AOMs While 13 state Medicaid programs covered at least one GLP-1 approved for weight management as of August 2024, states subsequently reversed course: California, New Hampshire, Pennsylvania, and South Carolina recently withdrew coverage
Many patients experience a decrease in appetite and initial weight loss within the first 1 to 2 weeks
Key players today include Mounjaro (tirzepatide) a dual-agonist of GLP-1 and GIP receptors and coming soon, Retatrutide a triple-receptor agonist (GLP-1, GIP and glucagon) that has shown even stronger early results
Save your confirmation email, use the tracking number, and allow extra time during high-demand promotions
This represents a significant convenience advantage over daily injection options like liraglutide (Saxenda)
Tirzepatide has shown robust improvements in blood pressure and fasting lipid levels